Rechercher une ressource pédagogique : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker

Le moteur de recherche des ressources pédagogiques donne accès à un ensemble de documents mis à disposition par l'Université Numérique, les établissements d'enseignement supérieur et Canal U. Vous y trouverez des productions universitaires dans l'ensemble des domaines de formation.

FILTRES

8 résultats
section 1 sur 1
résultats 1 à 8
Canal-U
Canal-U
01.12.2012
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker Speaker: Stefan BLANKENBERG, Hamburg, GER Discussant: Nancy GELLER, Bethesda, USA Abstract : Best statistical methods for evaluating the merits of a novel ma ...
  • Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Canal-U
Canal-U
01.12.2012
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker Speaker: Stefan BLANKENBERG, Hamburg, GER Discussant: Nancy GELLER, Bethesda, USA Abstract : Best statistical methods for evaluating the merits of a novel ma ...
  • Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Canal-U
Canal-U
01.12.2012
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures Speaker: Michael FELKER, Durham, USA Abstract : Biomarker guided-therapy: Are there other endpoints besides ...
  • Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Canal-U
Canal-U
01.12.2012
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates). Speaker: Stefan BLANKENBERG, Hamburg, GER Discussant: Nancy GELLER, Bethesda, USA Abstract : debate : Best statistical methods for evaluating ...
  • Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Canal-U
Canal-U
01.12.2012
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies? John JARCHO, Boston, USA, NEJM Rita REDBERG, San Francisco, ...
  • Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Canal-U
Canal-U
01.12.2012
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies? John JARCHO, Boston, USA, NEJM Rita REDBERG, San Francisco, ...
  • Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Canal-U
Canal-U
01.12.2012
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied? Speaker: Jim JANUZZI, Boston, USA Discussant: James SNIDER, Critical Diagnostics, USA Abstract : How should Diagnostic and Prognostic Markers Be Studied? The measurement of ...
  • Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Canal-U
Canal-U
01.12.2012
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied? Speaker: Jim JANUZZI, Boston, USA Discussant: James SNIDER, Critical Diagnostics, USA Abstract : How should Diagnostic and Prognostic Markers Be Studied? The measurement of ...
  • Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker